Related Experiment Videos
Diabetes and macrovascular disease
1Virginia Medical School and the Leonard R. Strelitz Diabetes Institutes, 855 West Brambleton Avenue Eastern, Norfolk, VA 23510, USA.
Insights
Diabetic patients face higher risks of cardiovascular disease (CVD) and macrovascular events like stroke and heart attack. Comprehensive management of risk factors, including glucose control and antiplatelet therapy, is crucial for prevention.
Area of Science:
- Endocrinology
- Cardiology
- Vascular Medicine
Background:
- Cardiovascular disease (CVD) is a leading cause of death in diabetic individuals.
- Macrovascular complications, such as stroke and myocardial infarction (MI), manifest earlier and more severely in diabetes.
- Diabetic arteriopathy involves endothelial dysfunction, hypercoagulability, altered blood flow, and platelet issues, accelerating macrovascular events.
Purpose of the Study:
- To review the impact of diabetes on cardiovascular health.
- To highlight the contribution of diabetic arteriopathy to macrovascular complications.
- To discuss strategies for preventing and managing CVD in diabetic patients.
Main Methods:
- Review of existing literature on diabetes and cardiovascular complications.
- Analysis of the pathophysiology of diabetic arteriopathy.
- Evaluation of therapeutic interventions for CVD risk reduction in diabetes.
Main Results:
- Diabetes significantly increases the risk and severity of macrovascular events.
- Diabetic arteriopathy is a key contributor to premature cardiovascular complications.
- Glycemic control, blood pressure management, and antiplatelet agents show efficacy in secondary prevention.
Conclusions:
- Aggressive management of all cardiovascular risk factors is essential for controlling the epidemic of macrovascular disease in diabetes.
- Optimal glycemic control, blood pressure, LDL levels, and dual antiplatelet therapy (aspirin and clopidogrel) are recommended.
- A multidisciplinary approach addressing all risk factors can contain the rising incidence of macrovascular disease in the diabetic population.
Abstract:
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in patients with diabetes. Macrovascular events, including stroke, myocardial infarction (MI), and peripheral arterial disease (PAD), occur earlier than in nondiabetics and the underlying pathologies are often more diffuse and severe. Diabetic arteriopathy, which encompasses endothelial dysfunction, hypercoagulability, changes in blood flow, and platelet abnormalities, contributes to the early evolution of these events. Tight glucose and blood pressure control improves the vascular status of these patients by varying degrees. Antiplatelet agents have also been shown to be effective in the secondary prevention of cardiovascular events. In the ideal world, every risk factor would be addressed and each diabetic would have excellent glycemic control, a low normal blood pressure, a low LDL, and be prescribed an ACE inhibitor, together with aspirin and clopidogrel. If this is done, this emerging epidemic of macrovascular disease will be contained.